PMID-sentid	Pub_year	Sent_text	compound_name	comp_offset	prot_official_name	organism	prot_offset
15963095-7	2005	The mean fluvoxamine-mediated percent increase in the AUC(0, infinity) of (R)-lansoprazole in the homEMs compared with the PMs was significant (P = 0.0117); however, C(max) did not differ among the three CYP2C19 genotypes.	Dexlansoprazole	74-90	cytochrome P450 family 2 subfamily C member 19	Homo sapiens	204-211
15448955-4	2004	RESULTS: The plasma concentrations of ( R)-lansoprazole were remarkably higher in all three CYP2C19 genotype groups than those of the corresponding ( S)-enantiomer.	Dexlansoprazole	38-55	cytochrome P450 family 2 subfamily C member 19	Homo sapiens	92-99
15537834-5	2005	R-Lansoprazole increased the Michaelis-Menten-derived V(max) of phenytoin 4-hydroxylation from 0.024 to 0.121 pmol/min/pmol P450, and lowered its K(m) from 20.5 to 15.0 microM, suggesting that R-lansoprazole activates CYP2C9-mediated phenytoin metabolism without displacing phenytoin from the active site.	Dexlansoprazole	0-14	cytochrome P450 family 2 subfamily C member 9	Homo sapiens	218-224
15537834-10	2005	Overall, these results suggest that R-lansoprazole activates CYP2C9 in a stereospecific and substrate-specific manner, possibly by binding within the active site and inducing positive cooperativity.	Dexlansoprazole	36-50	cytochrome P450 family 2 subfamily C member 9	Homo sapiens	61-67
15788366-4	2005	The estimated K(i) values determined for CYP2C19-catalysed S-mephenytoin 4"-hydroxylation were 0.6, 6.1, 3.4 and 5.7 microM for S-lansoprazole, R-lansoprazole, S-omeprazole and R-omeprazole, respectively.	Dexlansoprazole	144-158	cytochrome P450 family 2 subfamily C member 19	Homo sapiens	41-48
15537834-4	2005	R-Lansoprazole-mediated activation of the formation of 4-hydroxyphenytoin was also seen with recombinant human CYP2C9.	Dexlansoprazole	0-14	cytochrome P450 family 2 subfamily C member 9	Homo sapiens	111-117
35585299-7	2022	The selectivity tests of the developed SiO2-beta-CD@MIP/GCE sensor indicated a high specificity towards ESOM compared with structurally related competitor molecules such as R-omeprazole (R-OM), R-lansoprazole, and S-lansoprazole.	Dexlansoprazole	194-208	ACD shelterin complex subunit and telomerase recruitment factor	Homo sapiens	44-51
12152007-5	2002	RESULTS: The plasma concentrations of R(+)-lansoprazole were consistently higher than those of the S(-)-enantiomer in both extensive and poor metabolizers of CYP2C19, and the mean area under the plasma concentration-time curve of the (+)- and (-)-enantiomers showed 4.3- and 5.8-fold differences between poor and extensive metabolizers, respectively.	Dexlansoprazole	38-55	cytochrome P450 family 2 subfamily C member 19	Homo sapiens	158-165
29018343-3	2017	We have conducted a study to evaluate the influence of gastric H+/K+-ATPase, CYP2C19, and ABCB1 polymorphisms on the pharmacokinetic and pharmacodynamic profiles of dexlansoprazole injection in healthy Chinese subjects.	Dexlansoprazole	165-180	cytochrome P450 family 2 subfamily C member 19	Homo sapiens	77-84
29018343-3	2017	We have conducted a study to evaluate the influence of gastric H+/K+-ATPase, CYP2C19, and ABCB1 polymorphisms on the pharmacokinetic and pharmacodynamic profiles of dexlansoprazole injection in healthy Chinese subjects.	Dexlansoprazole	165-180	ATP binding cassette subfamily B member 1	Homo sapiens	90-95
27633629-7	2016	The assay was proved to be quite robust and with the novel assay we successfully identified dexlansoprazole (IC50 of 4.8 muM), a FDA-approved proton pump inhibitor, as a potential inhibitor for the PPI between IN and LEDGF/p75, which bound to the LEDGF/p75 partner with a kinetic dissociation (Kd) constant of 330 nM +- 2.6 nM.	Dexlansoprazole	92-107	latexin	Homo sapiens	121-124
28024166-9	2017	Recent studies in East Asian cohorts suggests that the potential of PPIs to attenuate the efficacy of clopidogrel could be minimized by the use of newer PPIs with weaker affinity for the CYP2C19 isoenzyme, namely, pantoprazole, dexlansoprazole, and rabeprazole.	Dexlansoprazole	228-243	cytochrome P450 family 2 subfamily C member 19	Homo sapiens	187-194
27633629-7	2016	The assay was proved to be quite robust and with the novel assay we successfully identified dexlansoprazole (IC50 of 4.8 muM), a FDA-approved proton pump inhibitor, as a potential inhibitor for the PPI between IN and LEDGF/p75, which bound to the LEDGF/p75 partner with a kinetic dissociation (Kd) constant of 330 nM +- 2.6 nM.	Dexlansoprazole	92-107	PC4 and SFRS1 interacting protein 1	Homo sapiens	217-226
27633629-7	2016	The assay was proved to be quite robust and with the novel assay we successfully identified dexlansoprazole (IC50 of 4.8 muM), a FDA-approved proton pump inhibitor, as a potential inhibitor for the PPI between IN and LEDGF/p75, which bound to the LEDGF/p75 partner with a kinetic dissociation (Kd) constant of 330 nM +- 2.6 nM.	Dexlansoprazole	92-107	PC4 and SFRS1 interacting protein 1	Homo sapiens	247-256
20687622-2	2010	In two large, identical, 8-week, randomized, double-blind, multicentre phase III trials, dexlansoprazole MR 60 mg once daily achieved complete healing in >or=92% of patients with all grades of erosive oesophagitis (primary endpoint) and was noninferior to lansoprazole 30 mg once daily using life-table analysis.	Dexlansoprazole	89-104	lectin, mannose binding 1	Homo sapiens	105-110
21118280-8	2011	As expected, serum gastrin values rose with dexlansoprazole therapy; increases were not dose related.	Dexlansoprazole	44-59	gastrin	Homo sapiens	19-26
19318694-0	2009	Effects of dexlansoprazole MR, a novel dual delayed release formulation of a proton pump inhibitor, on plasma gastrin levels in healthy subjects.	Dexlansoprazole	11-26	gastrin	Homo sapiens	110-117
20974316-0	2010	Dexlansoprazole: A proton pump inhibitor with a dual delayed-release system.	Dexlansoprazole	0-15	ATPase H+/K+ transporting subunit alpha	Homo sapiens	19-30
20974316-1	2010	BACKGROUND: Dexlansoprazole, the dextrorotatory enantiomer of lansoprazole, is a proton pump inhibitor (PPI) formulated to have dual delayed-release properties.	Dexlansoprazole	12-27	ATPase H+/K+ transporting subunit alpha	Homo sapiens	81-92
19392864-0	2009	Clinical trial: the effects of the proton pump inhibitor dexlansoprazole MR on daytime and nighttime heartburn in patients with non-erosive reflux disease.	Dexlansoprazole	57-72	ATPase H+/K+ transporting subunit alpha	Homo sapiens	35-46
20180789-3	2010	METHODS: In this randomized, open-label, four-way crossover study, 48 healthy subjects received dexlansoprazole MR 60 mg once daily 30 min before breakfast, lunch, dinner or an evening snack.	Dexlansoprazole	96-111	lectin, mannose binding 1	Homo sapiens	112-117
20167000-17	2009	CYP2C9 is activated by dapsone and its analogues and R-lansoprazole in a stereo-specific and substrate-dependent manner, probably through binding to the active site and inducing positive cooperativity.	Dexlansoprazole	53-67	cytochrome P450 family 2 subfamily C member 9	Homo sapiens	0-6
19318694-2	2009	The purpose of this study is to characterize the plasma gastrin (PG) profile associated with administration of dexlansoprazole MR. Forty-two healthy subjects receive dexlansoprazole MR 90 mg, dexlansoprazole MR 120 mg, and lansoprazole 30 mg once daily for 5 days in a randomized, open-label, 3-period crossover study with at least 14-day washout intervals.	Dexlansoprazole	111-126	gastrin	Homo sapiens	56-63
17190370-2	2006	The purpose of this study was to investigate the implication of the ABCB1 C3435Tpolymorphism on the pharmacokinetics of (R)-lansoprazole, the major enantiomer, in CYP2C19 extensive metabolizers (EMs) and on gastroesophageal symptoms in renal transplant recipients receiving tacrolimus.	Dexlansoprazole	120-136	ATP binding cassette subfamily B member 1	Homo sapiens	68-73
19067473-3	2009	As with lansoprazole, dexlansoprazole is metabolized mainly by CYP3A and CYP2C19.	Dexlansoprazole	22-37	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	63-68
19067473-3	2009	As with lansoprazole, dexlansoprazole is metabolized mainly by CYP3A and CYP2C19.	Dexlansoprazole	22-37	cytochrome P450 family 2 subfamily C member 19	Homo sapiens	73-80
19067473-4	2009	Based on in vitro studies, dexlansoprazole has the potential to inhibit activity of these isoenzymes and also may induce human hepatic CYP1A and CYP2C9 activity.	Dexlansoprazole	27-42	cytochrome P450 family 2 subfamily C member 9	Homo sapiens	145-151
19515014-9	2009	CYP2C9 is activated by dapsone and its analogues and R-lansoprazole in a stereo-specific and substrate-dependent manner, probably through binding to the active site and inducing positive cooperativity.	Dexlansoprazole	53-67	cytochrome P450 family 2 subfamily C member 9	Homo sapiens	0-6
17190370-2	2006	The purpose of this study was to investigate the implication of the ABCB1 C3435Tpolymorphism on the pharmacokinetics of (R)-lansoprazole, the major enantiomer, in CYP2C19 extensive metabolizers (EMs) and on gastroesophageal symptoms in renal transplant recipients receiving tacrolimus.	Dexlansoprazole	120-136	cytochrome P450 family 2 subfamily C member 19	Homo sapiens	163-170
17190370-7	2006	However, after renal transplantation, the peak plasma concentration (Cma ) and area under the plasma concentration-time curve (AUCO-24) of (R)-lansoprazole in patients with the ABCB1 C3435T C allele significantly increased, but not in patients with the TT genotype.	Dexlansoprazole	139-155	ATP binding cassette subfamily B member 1	Homo sapiens	177-182
17190370-10	2006	CONCLUSIONS: (R)-lansoprazole concentrations significantly increased in CYP2C19 extensive metabolizers with the ABCB1 C3435T C allele, but not TT genotype, after renal transplantation.	Dexlansoprazole	13-29	cytochrome P450 family 2 subfamily C member 19	Homo sapiens	72-79
17190370-10	2006	CONCLUSIONS: (R)-lansoprazole concentrations significantly increased in CYP2C19 extensive metabolizers with the ABCB1 C3435T C allele, but not TT genotype, after renal transplantation.	Dexlansoprazole	13-29	ATP binding cassette subfamily B member 1	Homo sapiens	112-117